Kohei Ikeda1, Eizo Marutani1, Shuichi Hirai1, Mark E Wood2, Matthew Whiteman3, Fumito Ichinose4. 1. Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 2. Department of Bioscience, College of Life and Environmental Science, University of Exeter, UK. 3. University of Exeter Medical School, St. Luke's Campus, Exeter, England, UK. Electronic address: m.whiteman@exeter.ac.uk. 4. Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: fichinose@mgh.harvard.edu.
Abstract
AIMS: Mitochondria-targeted hydrogen sulfide donor AP39, [(10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-5yl)phenoxy)decyl) triphenylphosphonium bromide], exhibits cytoprotective effects against oxidative stress in vitro. We examined whether or not AP39 improves the neurological function and long term survival in mice subjected to cardiac arrest (CA) and cardiopulmonary resuscitation (CPR). METHODS: Adult C57BL/6 male mice were subjected to 8 min of CA and subsequent CPR. We examined the effects of AP39 (10, 100, 1000 nmol kg(-1)) or vehicle administered intravenously at 2 min before CPR (Experiment 1). Systemic oxidative stress levels, mitochondrial permeability transition, and histological brain injury were assessed. We also examined the effects of AP39 (10, 1000 nmol kg(-1)) or vehicle administered intravenously at 1 min after return of spontaneous circulation (ROSC) (Experiment 2). ROSC was defined as the return of sinus rhythm with a mean arterial pressure >40 mm Hg lasting at least 10 seconds. RESULTS: Vehicle treated mice subjected to CA/CPR had poor neurological function and 10-day survival rate (Experiment 1; 15%, Experiment 2; 23%). Administration of AP39 (100 and 1000 nmol kg(-1)) 2 min before CPR significantly improved the neurological function and 10-day survival rate (54% and 62%, respectively) after CA/CPR. Administration of AP39 before CPR attenuated mitochondrial permeability transition pore opening, reactive oxygen species generation, and neuronal degeneration after CA/CPR. Administration of AP39 1 min after ROSC at 10 nmol kg(-1), but not at 1000 nmol kg(-1), significantly improved the neurological function and 10-day survival rate (69%) after CA/CPR. CONCLUSION: The current results suggest that administration of mitochondria-targeted sulfide donor AP39 at the time of CPR or after ROSC improves the neurological function and long term survival rates after CA/CPR by maintaining mitochondrial integrity and reducing oxidative stress.
AIMS: Mitochondria-targeted hydrogen sulfide donor AP39, [(10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-5yl)phenoxy)decyl) triphenylphosphonium bromide], exhibits cytoprotective effects against oxidative stress in vitro. We examined whether or not AP39 improves the neurological function and long term survival in mice subjected to cardiac arrest (CA) and cardiopulmonary resuscitation (CPR). METHODS: Adult C57BL/6 male mice were subjected to 8 min of CA and subsequent CPR. We examined the effects of AP39 (10, 100, 1000 nmol kg(-1)) or vehicle administered intravenously at 2 min before CPR (Experiment 1). Systemic oxidative stress levels, mitochondrial permeability transition, and histological brain injury were assessed. We also examined the effects of AP39 (10, 1000 nmol kg(-1)) or vehicle administered intravenously at 1 min after return of spontaneous circulation (ROSC) (Experiment 2). ROSC was defined as the return of sinus rhythm with a mean arterial pressure >40 mm Hg lasting at least 10 seconds. RESULTS: Vehicle treated mice subjected to CA/CPR had poor neurological function and 10-day survival rate (Experiment 1; 15%, Experiment 2; 23%). Administration of AP39 (100 and 1000 nmol kg(-1)) 2 min before CPR significantly improved the neurological function and 10-day survival rate (54% and 62%, respectively) after CA/CPR. Administration of AP39 before CPR attenuated mitochondrial permeability transition pore opening, reactive oxygen species generation, and neuronal degeneration after CA/CPR. Administration of AP39 1 min after ROSC at 10 nmol kg(-1), but not at 1000 nmol kg(-1), significantly improved the neurological function and 10-day survival rate (69%) after CA/CPR. CONCLUSION: The current results suggest that administration of mitochondria-targeted sulfide donor AP39 at the time of CPR or after ROSC improves the neurological function and long term survival rates after CA/CPR by maintaining mitochondrial integrity and reducing oxidative stress.
Authors: Kotaro Kida; Shizuka Minamishima; Huifang Wang; JiaQian Ren; Kazim Yigitkanli; Ala Nozari; Joseph B Mandeville; Philip K Liu; Christina H Liu; Fumito Ichinose Journal: Resuscitation Date: 2012-02-25 Impact factor: 5.262
Authors: Bartosz Szczesny; Katalin Módis; Kazunori Yanagi; Ciro Coletta; Sophie Le Trionnaire; Alexis Perry; Mark E Wood; Matthew Whiteman; Csaba Szabo Journal: Nitric Oxide Date: 2014-04-19 Impact factor: 4.427
Authors: Jürgen Knapp; Anna Heinzmann; Andreas Schneider; Stephan A Padosch; Bernd W Böttiger; Peter Teschendorf; Erik Popp Journal: Resuscitation Date: 2011-04-20 Impact factor: 5.262
Authors: Matthew Whiteman; Nam Sang Cheung; Yi-Zhun Zhu; Siew Hwa Chu; Jia Ling Siau; Boon Seng Wong; Jeffrey S Armstrong; Philip K Moore Journal: Biochem Biophys Res Commun Date: 2005-01-28 Impact factor: 3.575
Authors: John W Elrod; John W Calvert; Joanna Morrison; Jeannette E Doeller; David W Kraus; Ling Tao; Xiangying Jiao; Rosario Scalia; Levente Kiss; Csaba Szabo; Hideo Kimura; Chi-Wing Chow; David J Lefer Journal: Proc Natl Acad Sci U S A Date: 2007-09-18 Impact factor: 11.205
Authors: Matthew Whiteman; Ling Li; Peter Rose; Choon-Hong Tan; David B Parkinson; Philip K Moore Journal: Antioxid Redox Signal Date: 2010-05-15 Impact factor: 8.401
Authors: Qutuba G Karwi; Julia Bornbaum; Kerstin Boengler; Roberta Torregrossa; Matthew Whiteman; Mark E Wood; Rainer Schulz; Gary F Baxter Journal: Br J Pharmacol Date: 2017-01-24 Impact factor: 8.739
Authors: Claire L Allen; Katarzyna Wolanska; Naseeb K Malhi; Andrew V Benest; Mark E Wood; Winfried Amoaku; Roberta Torregrossa; Matthew Whiteman; David O Bates; Jacqueline L Whatmore Journal: Front Cell Dev Biol Date: 2021-09-07
Authors: Rudolf Wedmann; Constantin Onderka; Shengwei Wei; István András Szijártó; Jan Lj Miljkovic; Aleksandra Mitrovic; Mike Lange; Sergey Savitsky; Pramod Kumar Yadav; Roberta Torregrossa; Ellen G Harrer; Thomas Harrer; Isao Ishii; Maik Gollasch; Mark E Wood; Erwan Galardon; Ming Xian; Matthew Whiteman; Ruma Banerjee; Milos R Filipovic Journal: Chem Sci Date: 2016-02-19 Impact factor: 9.825
Authors: Eva Latorre; Roberta Torregrossa; Mark E Wood; Matthew Whiteman; Lorna W Harries Journal: Aging (Albany NY) Date: 2018-07-19 Impact factor: 5.682
Authors: Domokos Gerő; Roberta Torregrossa; Alexis Perry; Alicia Waters; Sophie Le-Trionnaire; Jacqueline L Whatmore; Mark Wood; Matthew Whiteman Journal: Pharmacol Res Date: 2016-08-23 Impact factor: 7.658